Ancora Advisors LLC Boosts Stock Holdings in Omeros Corporation $OMER

Key Points

• Ancora Advisors increased its Omeros stake by 46.7% in the second quarter, holding 168,750 shares worth approximately $1.6 million. Institutional investors collectively own 48.79% of Omeros.
• Omeros reported quarterly earnings of $0.02 per share, beating the consensus estimate of a $0.27 loss, while revenue of $28.53 million exceeded expectations. The stock opened at $18.86, near its 52-week high of $19.65.
• Insiders have sold 95,906 shares worth about $1.78 million over the past three months. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $38.00.

Ancora Advisors LLC lifted its position in shares of Omeros Corporation (NASDAQ:OMER - Free Report) by 46.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 168,750 shares of the biopharmaceutical company's stock after acquiring an additional 53,750 shares during the period. Ancora Advisors LLC owned approximately 0.23% of Omeros worth $1,605,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in OMER. International Assets Investment Management LLC raised its stake in shares of Omeros by 16.0% in the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 800 shares during the last quarter. State of Wyoming bought a new stake in Omeros in the 4th quarter worth approximately $25,000. AQR Capital Management LLC grew its position in Omeros by 7.2% in the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 1,532 shares during the period. ProShare Advisors LLC raised its stake in Omeros by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company's stock valued at $261,000 after buying an additional 1,637 shares during the last quarter. Finally, Cerity Partners LLC raised its stake in Omeros by 6.1% during the 4th quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company's stock valued at $523,000 after buying an additional 1,750 shares during the last quarter. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Omeros

In other news, Director Arnold C. Hanish sold 10,000 shares of Omeros stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the director directly owned 5,000 shares of the company's stock, valued at approximately $94,750. The trade was a 66.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO David J. Borges sold 10,000 shares of the business's stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the completion of the sale, the chief accounting officer owned 5,906 shares in the company, valued at $111,918.70. This represents a 62.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 95,906 shares of company stock worth $1,780,205. 10.50% of the stock is currently owned by company insiders.

Omeros Stock Up 0.6%

NASDAQ:OMER opened at $18.86 on Thursday. The business's 50-day simple moving average is $13.14 and its two-hundred day simple moving average is $12.19. Omeros Corporation has a 52 week low of $3.94 and a 52 week high of $19.65. The stock has a market cap of $1.37 billion, a PE ratio of 14.73 and a beta of 2.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Sell-side analysts anticipate that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on OMER. Zacks Research cut Omeros from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Weiss Ratings raised shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. Finally, HC Wainwright reissued a "buy" rating on shares of Omeros in a report on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $38.00.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.